Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves may spot schizophrenia early: new study

NCT ID NCT07604129

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive brain ultrasound, combined with machine learning, can help distinguish people with schizophrenia from healthy individuals. Researchers will scan 200 adults (100 with schizophrenia, 100 without) and measure specific brain features. The goal is to build a computer model that could one day aid doctors in earlier diagnosis, though it will not replace standard psychiatric evaluation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial sonography (brain ultrasound)
What this could lead to
If successful, this could give doctors a new, non-invasive tool to help diagnose schizophrenia earlier, especially in unclear cases.
What could go wrong
This is an early-stage study with only 200 participants. The model is a research tool and won't replace a psychiatrist's diagnosis. It may not work well in broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 to 65 years will be recruited from Taizhou Second People's Hospital and related recruitment channels. The study population will include participants with schizophrenia diagnosed according to ICD-10 criteria and healthy control participants without a personal or family history of psychiatric disorders. Healthy controls will be matched as far as possible to the schizophrenia group by basic demographic characteristics. All participants will undergo baseline transcranial sonography assessment and clinical data collection.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Schizophrenia group: 1. Adults aged 18 to 65 years. 2. Diagnosis of schizophrenia according to ICD-10 criteria by a psychiatrist. 3. Able to complete clinical assessment and transcranial sonography examination. 4. No other severe physical disease, neurological disease, or major psychiatric disorder. 5. Written informed consent provided by the participant or legally authorized representative. Healthy control group: 1. Adults aged 18 to 65 years. 2. No personal history of psychiatric disorders. 3. No family history of psychiatric disorders. 4. No severe physical disease, neurological disease, or major psychiatric disorder. 5. Basic demographic characteristics matched as far as possible to the schizophrenia group. 6. Able to complete clinical assessment and transcranial sonography examination. 7. Written informed consent provided by the participant or legally authorized representative. Exclusion Criteria: 1. Severe physical disease or neurological disease. 2. History of drug or alcohol abuse. 3. Inability to complete clinical assessment or transcranial sonography examination. 4. Inadequate temporal acoustic window or poor image quality preventing valid transcranial sonography measurements. 5. Acute or clinically unstable state that prevents completion of study procedures. 6. Comorbid major psychiatric disorder, such as major depressive disorder. 7. Refusal or withdrawal of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Taizhou Second People's Hospital

    Taizhou, Zhejiang, 317200, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.